vTv Therapeutics (NASDAQ:VTVT) Announces Quarterly Earnings Results, Beats Estimates By $0.32 EPS

vTv Therapeutics (NASDAQ:VTVT) announced its earnings results on Thursday. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.32, Zacks reports.

vTv Therapeutics Stock Down 3.6 %

vTv Therapeutics stock traded down $0.65 during trading hours on Thursday, reaching $17.61. 66,178 shares of the company’s stock were exchanged, compared to its average volume of 23,309. The firm’s 50 day simple moving average is $16.85 and its 200 day simple moving average is $15.42. vTv Therapeutics has a twelve month low of $12.12 and a twelve month high of $30.99. The firm has a market capitalization of $56.18 million, a PE ratio of -3.89 and a beta of 1.07.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on VTVT. Alliance Global Partners began coverage on vTv Therapeutics in a research report on Monday, December 9th. They set a “buy” rating and a $35.00 target price for the company. StockNews.com began coverage on vTv Therapeutics in a research report on Wednesday. They set a “sell” rating for the company.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.